What is INSM's market cap?

$24.13B, based on the Nov 4 close of $110.00.

Does Insmed pay a dividend?

No regular cash dividend has been paid in the last year.

How much of INSM is sold short?

13.5M shares, 6.3% of float, as of Oct 15, 2026.

What sector is INSM in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · INSMHealthcarePharmaceuticals

Insmed, Inc. (INSM)

$110.00+5.32%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$109.88▼ 41.00% in range

Nov 3, 2025Low $91.88 · High $211.41Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Insmed closed at $110.00 on Nov 4, up 5.32%, 48.0% below its 52-week closing high. Volume of 4.9M shares was 1.30× its 20-day average (above normal).

Split-adjusted performance: +4.5% over one month, -19.8% over six months, -40.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $524.43M, up 268.4% from a year earlier, with a net margin of -19.1%.

Short interest was 13.5M shares at the Oct 15 settlement, down 2.3% from the prior report (6.3% of float, 4.1 days to cover).

Market cap$24.13B219.4M shares

Revenue · quarter$524.4M+268.4% YoY

Diluted EPS$-0.46—

P/E · TTM—P/S 15.9×

Net margin-19.1%Gross 85.1%

Dividend yieldNone

52-week range91.88 – 211.41−48.0% from high

Volume4.9M1.30× 20-day avg

Volatility · 60d48.6%Annualised

Short % of float6.3%4.1 days to cover

Net cash$569.9MCash $1.15B

Next earnings—Not scheduled

Split-adjusted performance

1W +13.4%1M +4.5%3M −17.0%6M −19.8%YTD −36.8%1Y −40.9%3Y +362.2%5Y +316.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum57

Revenue growth91

Net margin57

Value (low P/E)—

Size97

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short13.5M−2.3% vs prior

Days to cover4.1Settled Oct 15

% of float6.3%

Short vol. 10d40.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
INSMInsmed	$110.00	+5.32%	−19.8%	+268.4%	−19.1%	—	$24.13B
UTHRUnited Therapeutics	$608.49	+1.19%	+2.0%	−1.9%	42.5%	19.9	$26.10B	Compare
VTRSViatris	$19.22	+1.59%	+20.5%	+4.9%	−3.2%	—	$22.08B	Compare
ALNYAlnylam Pharmaceuticals	$161.08	+0.74%	−46.8%	+16.7%	148.6%	7.9	$21.57B	Compare
ROIVRoivant Sciences	$38.23	+6.08%	+32.7%	−33.5%	−13164.8%	—	$27.61B	Compare
RPRXRoyalty Pharma	$67.56	+1.75%	+33.2%	+16.5%	2.7%	36.9	$30.08B	Compare
ZTSZOETIS	$89.20	+7.48%	−19.8%	−0.2%	28.0%	14.1	$36.86B	Compare
JAZZJazz Pharmaceuticals	$234.66	+2.14%	+2.7%	+10.4%	−38.9%	74.0	$15.23B	Compare
BBIOBridgeBio Pharma	$77.89	+5.21%	+14.4%	+192.6%	−23.5%	—	$15.17B	Compare

News about Insmed

All news →

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceZacks Investment Research · 5d ago▲ Positive Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research · Oct 22, 2026▼ Negative INSM Stock Slides on CFO Exit, Reiterates '26 Sales ViewZacks Investment Research · Oct 6, 2026▼ Negative FDA Accepts Insmed's Filing Seeking Label Expansion for ArikayceZacks Investment Research · Sep 22, 2026▲ Positive Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Zacks Investment Research · Aug 27, 2026▲ Positive

Quick answers

What does Insmed do?: Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare.
What is INSM's market cap?: $24.13B, based on the Nov 4 close of $110.00.
Does Insmed pay a dividend?: No regular cash dividend has been paid in the last year.
How much of INSM is sold short?: 13.5M shares, 6.3% of float, as of Oct 15, 2026.
What sector is INSM in?: Healthcare, in the Pharmaceuticals industry.

About Insmed

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

HQ: Bridgewater, NJ1,664 employeesListed Jun 1, 2000insmed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology